Moreover, several clinical trials of selective CDK4/6i for advanced solid cancers are ongoing40, as genetic alterations predicted to drive the hyper-activation of CyclinD-CDK4/6 are common in various cancers. The gene discussed is CDK4; the disease is cancer.